PriceTargets.com logo

Liminal BioSciences - LMNL Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$8.50 As of 09/26/2023 09:00 PM ET
▲ +0.01 (0.12%)
Get New Liminal BioSciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LMNL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LMNL

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Liminal BioSciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $8.50.

This chart shows the closing price for LMNL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Liminal BioSciences. This rating has held steady since April 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/9/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/5/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/30/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/10/2023Bloom BurtonUpgradeSell ➝ Hold
6/24/2021HC WainwrightDowngradeBuy ➝ Neutral
6/7/2021HC WainwrightReiterated RatingBuy$110.00
6/1/2021Piper SandlerDowngradeOverweight ➝ Neutral$220.00 ➝ $45.00
3/26/2021Leede Jones GabReiterated RatingHold
2/18/2021HC WainwrightInitiated CoverageBuy$110.00
1/29/2021Bloom BurtonDowngradeHold ➝ Sell
12/21/2020Piper SandlerInitiated CoverageOverweight$220.00
10/5/2020Bloom BurtonReiterated RatingHold
8/11/2020Echelon Wealth PartnersReiterated RatingHold
7/3/2020Echelon Wealth PartnersReiterated RatingHold$210.00
(Data available from 12/30/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Liminal BioSciences logo
Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
Read More

Today's Range

Now: $8.50
Low: $8.48
High: $8.50

50 Day Range

MA: $8.47
Low: $8.38
High: $8.50

52 Week Range

Now: $8.50
Low: $3.10
High: $8.50

Volume

5,000 shs

Average Volume

63,470 shs

Market Capitalization

$26.35 million

P/E Ratio

29.31

Dividend Yield

N/A

Beta

1.03

Frequently Asked Questions

What sell-side analysts currently cover shares of Liminal BioSciences?

The following Wall Street sell-side analysts have issued research reports on Liminal BioSciences in the last year:
View the latest analyst ratings for LMNL.

What is the current price target for Liminal BioSciences?

0 Wall Street analysts have set twelve-month price targets for Liminal BioSciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Liminal BioSciences in the next year.
View the latest price targets for LMNL.

What is the current consensus analyst rating for Liminal BioSciences?

Liminal BioSciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for LMNL.

What other companies compete with Liminal BioSciences?

Other companies that are similar to Liminal BioSciences include MediciNova, Assembly Biosciences, OS Therapies, Nuvectis Pharma and Regulus Therapeutics. Learn More about companies similar to Liminal BioSciences.

How do I contact Liminal BioSciences' investor relations team?

Liminal BioSciences' physical mailing address is 440 Armand-Frappier Boulevard Suite 300, Laval A8, H7V 4B4. The company's listed phone number is 1-450-781-0115 and its investor relations email address is [email protected]. The official website for Liminal BioSciences is www.liminalbiosciences.com. Learn More about contacing Liminal BioSciences investor relations.